4.7 Article

High-Titer Production of the Fungal Anhydrotetracycline, TAN-1612, in Engineered Yeasts

Journal

ACS SYNTHETIC BIOLOGY
Volume -, Issue -, Pages -

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acssynbio.2c00116

Keywords

TAN-1612; anhydrotetracycline; Saccharomyces cerevisiae; Saccharomyces boulardii; efflux pumps

Funding

  1. NIH [R01 AI110794, R01 GM134293]
  2. HHMI Gilliam Fellowships for Advanced Study program [GT14999]

Ask authors/readers for more resources

Antibiotic resistance is a global health threat, and developing new tetracycline analogue therapeutics is urgent. By engineering yeast, researchers have successfully produced the fungal tetracycline TAN-1612 and significantly increased its yield. This study marks an important step in combating antibiotic resistance.
Antibiotic resistance is a growing global health threat, demanding urgent responses. Tetracyclines, a widely used antibiotic class, are increasingly succumbing to antibiotic resistance; generating novel analogues is therefore a top priority for public health. Fungal tetracyclines provide structural and enzymatic diversity for novel tetracycline analogue production in tractable heterologous hosts, like yeasts, to combat antibiotic-resistant pathogens. Here, we successfully engineered Saccharomyces cerevisiae (baker's yeast) and Saccharomyces boulardii (probiotic yeast) to produce the nonantibiotic fungal anhydrote-tracycline, TAN-1612, in synthetic defined media-necessary for dean purifications-through heterologously expressing TAN-1612 genes mined from the fungus, Aspergillus niger ATCC 1015. This was accomplished via (i) a promoter library-based combinatorial pathway optimization of the biosynthetic TAN-1612 genes coexpressed with a putative TAN-1612 efflux pump, reducing TAN-1612 toxicity in yeasts while simultaneously increasing supernatant titers and (ii) the development of a medium-throughput UV-visible spectrophotometric assay that facilitates TAN-1612 combinatorial library screening. Through this multipronged approach, we optimized TAN-1612 production, yielding an over 450-fold increase compared to previously reported S. cerevisiae yields. TAN-1612 is an important tetracycline analogue precursor, and we thus present the first step toward generating novel tetracycline analogue therapeutics to combat current and emerging antibiotic resistance. We also report the first heterologous production of a fungal polyketide, like TAN-1612, in the probiotic S. boulardii. This highlights that engineered S. boulardii can biosynthesize complex natural products like tetracyclines, setting the stage to equip probiotic yeasts with synthetic therapeutic finictionalities to generate living therapeutics or biocontrol agents for clinical and agricultural applications.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available